Parabilis Medicines closed a $305 million Series F financing led by RA Capital, Fidelity and Janus Henderson to advance zolucatetide (FOG-001) toward Phase III for desmoid tumors. The company said the funds will support late-stage development after Fast Track designation from the FDA and earlier Phase I/II signals of activity. Parabilis (formerly FogPharma) positions its Helicon platform to target intracellular and previously undruggable pathways; zolucatetide inhibits β‑catenin–TCF interaction, a key driver in desmoid tumor proliferation. The raise prompted market speculation about a potential IPO as the company scales pivotal trials.